– Genesys has consistently delivered strong performance and increasing DPI across its funds, moving from upper quartile to upper decile in Fund III.
– Recent notable exits include:
▪️Inversago Pharma ($1.4B acquisition by Novo Nordisk)
▪️Fusion Pharmaceuticals ($3.3B acquisition by AstraZeneca)
– Genesys combines capital and expertise to co-create Canadian life science companies that compete globally.
– Recognized as a trusted local partner for global syndicates and repeat entrepreneurs.
– Maintains a value-added, partnership approach with scientific founders to build anchor companies.
– Genesys aims to continue setting the standard for life sciences VC in Canada.
– Guillermo Freire, Senior Vice-President, Mid-Market Group, EDC.: Genesys helps foster ecosystem clusters, driving innovation and Canada’s global competitiveness in life sciences.
– Maxime Pesant CPA, CFA, Vice-President, Private Equity and Impact Investing Life Sciences, at the Fonds de solidarité FTQ.: Reinvestment shows confidence in Genesys’ local expertise and impact on Quebec’s biotech sector.
– Senia Rapisarda, LL.M, CIM, Managing Director, HarbourVest Partners: Supporting Canadian life sciences with Genesys is a strategic move for innovation and economic diversification.
– Damian Lamb, Co-founder and Managing Director, Genesys Capital: It’s a great time to invest in biopharma and medtech companies leveraging local innovation.
– Steve Romanyshyn, President and Chief Executive Officer at Venture Ontario: Ontario is a leader in life sciences; Genesys helps high-potential companies scale globally.
– The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions: VCCI co-investment strategy supports Canada’s thriving life sciences sector and ensures global competitiveness.
– Fund IV welcomes new Limited Partners (LPs) and thanks returning LPs for early and catalytic commitments amid a challenging macro environment.
– Institutional investors in Fund IV include:
▪️ BDC Capital
▪️ Export Development Canada | Exportation et développement Canada
▪️ Fonds de solidarité FTQ
▪️ HarbourVest Partners
▪️ RBC
▪️ Teralys Capital
▪️ venture ontario
▪️ Government of Canada’s Venture Capital Catalyst Initiative (VCCI), administered by BDC Capital
– Genesys has consistently delivered strong performance and increasing DPI across its funds, moving from upper quartile to upper decile in Fund III.
– Recent notable exits include:
▪️Inversago Pharma ($1.4B acquisition by Novo Nordisk)
▪️Fusion Pharmaceuticals ($3.3B acquisition by AstraZeneca)
– Genesys combines capital and expertise to co-create Canadian life science companies that compete globally.
– Recognized as a trusted local partner for global syndicates and repeat entrepreneurs.
– Maintains a value-added, partnership approach with scientific founders to build anchor companies.
– Genesys aims to continue setting the standard for life sciences VC in Canada.
– Guillermo Freire, Senior Vice-President, Mid-Market Group, EDC.: Genesys helps foster ecosystem clusters, driving innovation and Canada’s global competitiveness in life sciences.
– Maxime Pesant CPA, CFA, Vice-President, Private Equity and Impact Investing Life Sciences, at the Fonds de solidarité FTQ.: Reinvestment shows confidence in Genesys’ local expertise and impact on Quebec’s biotech sector.
– Senia Rapisarda, LL.M, CIM, Managing Director, HarbourVest Partners: Supporting Canadian life sciences with Genesys is a strategic move for innovation and economic diversification.
– Damian Lamb, Co-founder and Managing Director, Genesys Capital: It’s a great time to invest in biopharma and medtech companies leveraging local innovation.
– Steve Romanyshyn, President and Chief Executive Officer at Venture Ontario: Ontario is a leader in life sciences; Genesys helps high-potential companies scale globally.
– The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions: VCCI co-investment strategy supports Canada’s thriving life sciences sector and ensures global competitiveness.